• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pediatr Infect Dis J . Worse Neurologic Outcomes Observed in Pediatric COVID-19-associated Encephalopathy Than in Influenza-associated Encephalopat

tetano

Editor, Senior Moderator
Pediatr Infect Dis J


. 2025 Nov 7.
doi: 10.1097/INF.0000000000005040. Online ahead of print. Worse Neurologic Outcomes Observed in Pediatric COVID-19-associated Encephalopathy Than in Influenza-associated Encephalopathy

Haruka Takei[SUP] 1 [/SUP], Mihoko Furuichi[SUP] 1 [/SUP], Kenjiro Kikuchi[SUP] 2 [/SUP], Chikara Ogimi[SUP] 3 [/SUP], Tomoya Takeuchi[SUP] 4 [/SUP], Munehiro Furuichi[SUP] 5 [/SUP], Yuto Otsubo[SUP] 6 [/SUP], Mitsuo Motobayashi[SUP] 7 [/SUP], Shota Yamamoto[SUP] 8 [/SUP], Ryohei Futatsugi[SUP] 9 [/SUP], Eisuke Suganuma[SUP] 1 [/SUP]



Affiliations
Abstract

Background: Pediatric coronavirus disease (COVID-19)-associated encephalopathy can lead to severe neurologic complications. However, data comparing it with other infectious encephalopathies are limited. This study aimed to compare the clinical characteristics of COVID-19-associated encephalopathy with those of influenza-associated encephalopathy, which serves as a representative model of severe infectious encephalopathy in Japan. Additionally, we assessed the factors associated with a poor prognosis.
Methods: We conducted a retrospective cohort study of patients with COVID-19- and influenza-associated encephalopathy admitted to 7 children's hospitals in Japan between January 2017 and December 2023. Clinical characteristics were compared using the Mann-Whitney U test and Fisher exact test. Additionally, logistic regression analysis was performed to identify factors associated with a pediatric cerebral performance category score ≥4 at discharge.
Results: A total of 89 patients were included: 29 in the COVID-19 group and 60 in the influenza group. Demographics and initial clinical characteristics were similar between groups. However, a significantly higher proportion of patients in the COVID-19 group had a pediatric cerebral performance category score ≥4 at discharge (37.9% vs. 16.7%, P = 0.04). In each of the 3 separate multivariable models, COVID-19, the presence of underlying neurologic conditions and shorter time from onset to encephalopathy diagnosis were independently associated with poor prognosis.
Conclusions: The clinical characteristics of the 2 groups were similar; however, patients with COVID-19-associated encephalopathy showed worse discharge neurologic outcomes, warranting cautious interpretation. Enhancing public awareness of the severe outcomes and conducting further research is essential for better understanding its pathogenesis and treatment.

Keywords: COVID-19; encephalopathy; influenza; outcomes; pediatric.

 
Back
Top